Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New fluid lens could sharpen vision after cataract surgery

NCT ID NCT05317728

Disease control Sponsor: Alcon Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study tests a new type of lens implant for people having cataract surgery. The lens uses fluid to adjust focus, aiming to improve vision compared to a standard fixed-focus lens. About 175 participants will receive either the new lens or a standard one, and their vision and any complications will be tracked over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fluid accommodating intraocular lens (IOL) implant
What this could lead to
If it works, this lens could provide better distance vision after cataract surgery than standard lenses, reducing the need for glasses.
What could go wrong
This is a relatively small, early-stage study (175 participants) comparing a new device to an existing one. The new lens may not show significant improvement or could have unexpected side effects like any surgical implant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

175 people

The number who actually took part.

Started

Mar 2023

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Able to understand and sign an Institutional Review Board / International Ethics Committee approved informed Consent form; * Willing and able to attend all scheduled study visits as required by the protocol; * Diagnosed with bilateral cataracts requiring removal by phacoemulsification with a clear corneal incision; * Other protocol-specified inclusion criteria may apply. Key Exclusion Criteria: * Subjects taking medications that may affect accommodation; * Clinically significant eye abnormalities as specified in the protocol; * Previous eye surgery as specified in the protocol; * Other protocol-specified exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract

Contacts and locations

Locations

  • Asociación Para Evitar la Ceguera en México

    Mexico City, 04030, Mexico

  • Centro de Retina Medica y Quirurgica SC

    Zapopan, Jalisco, 45116, Mexico

  • Clinica 20/20

    San José, Costa Rica

  • Laser Center SA

    Santo Domingo, 10124, Dominican Republic

  • Panama Eye Center

    Panama City, Panama

  • Salauno Salud SAPI de CV

    Mexico City, 06600, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.